Amphotericin B plus fluconazole for HIV-associated cryptococcal meningitis

Clinical Infectious Diseases

Volumn 48, Issue 12, 2009, Pages 1784-1786

  Horrison, Thomas S ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; FLUCYTOSINE; NEVIRAPINE; WARFARIN;

BLEEDING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CRYPTOCOCCAL MENINGITIS; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOW DRUG DOSE; MORTALITY; NAUSEA; NEPHROTOXICITY; NONHUMAN; NOTE; PRIORITY JOURNAL; PSYCHOSIS; TREATMENT OUTCOME;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CLINICAL TRIALS AS TOPIC; FLUCONAZOLE; HIV INFECTIONS; HUMANS; MENINGITIS, CRYPTOCOCCAL; TREATMENT OUTCOME;

EID: 66949178007     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/599113     Document Type: Note

References (12)

1. Pappas PG, Chetchotisakd P, Larsen R, et al. A phase II randomized trial of amphotericin B alone or combined with ?uconazole in the treatment of HIV-associated cryptococcal meningitis. Clin Infect Dis 2009; 48:1775-83 (in this issue).
2. Rex JH, Pappas PG, Karchmer AW, et al. A randomized and blinded multicenter trial of high-dose ?uconazole plus placebo versus ?uconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 2003;36:1221-8.
3. Brouwer AE, Rajanuwong A, Chierakul W, et al. Combination antifungal therapies forHIV-associated cryptococcalmeningitis: a randomised trial. Lancet 2004; 363:1764-7.
4. Larsen RA, Bauer M, Thomas AM, Graybill JR. Amphotericin B and ?uconazole, a potent combination therapy for cryptococcal meningitis. Antimicrob Agents Chemother 2004;48:985-91.
5. Diamond DM, BauerM, Daniel BE, et al. Amphotericin B colloidal dispersion combined with ?ucytosine with or without ?uconazole for treatment of murine cryptococcal meningitis. Antimicrob Agents Chemother 1998;42:528-33.
6. Longley N,Muzoora C, Taseera K, et al. Dose-response effect of high dose ?uconazole for HIV-associated cryptococcal meningitis in Southwest Uganda. Clin Infect Dis 2008;47:1556-61.
7. Milefchik E, Leal MA, Haubrich R, et al. Fluconazole alone or combined with ?ucytosine for the treatment of AIDS-associated crypto coccal meningitis.MedMycol 2008; 46:393-5.
8. ManosuthiW, Athichathanabadi C, Uttayamakul S, Phoorisri T, Sungkanuparph S. Plasma nevirapine levels, adverse eventsand ef?cacy of antiretroviral therapy among HIV-infected patients concurrently receiving nevirapine-based antiretroviral therapy and ?uconazole. BMC Infect Dis 2007; 7:14.
9. Manosuthi W, Chumpathat N, Chaovavanich A, Sungkanuparph S. Safety and tolerability of nevirapine-based antiretroviral therapy in HIV-infected patients receiving ?uconazole for cryptococcal prophylaxis: a retrospective cohort study. BMC Infect Dis 2005; 5:67.
10. Saag MS, Graybill RJ, Larsen RA, et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis 2000; 30:710-8.
11. Zolopa A, Andersen J, Komarow L, et al. Immediate vs. deferred ART in the setting of acute AIDS-related opportunistic infection: ?nal results of a randomized strategy trial, ACTG A5164 [abstract 142]. In: Program and abstracts of the 15th Conference of Retroviruses and Opportunistic Infections (Boston). 2008. Available at: http://www.retroconference.org/2008/data/?les/retro2008- frameset.htm. Accessed 2 March 2009.
12. Makadzange AT, Ndhluvu C, Takarinda K, et al. Early vs delayed ART in the treatment of cryptococcal meningitis in Africa [abstract 36cLB]. In: Program and abstracts of the 16th Conference on Retroviruses and Opportunistic Infections (Montreal). 2009. Available at: http://www.retroconference.org/2009/ data/?les/webcast.htm. Accessed 2 March 2009.